盐酸酚苄明
盐酸酚苄明 性质
| 熔点 | 137.5°C |
|---|---|
| 储存条件 | 15-25°C |
| 溶解度 | 溶于乙醇、DMSO、二甲基甲酰胺(DMF)等有机溶剂。 |
| 形态 | 粉末 |
| 酸度系数(pKa) | pKa 4.4 (Uncertain) |
| 颜色 | 白色 |
| 水溶解性 | <0.01 g/100 mL at 18.5 ºC |
| Merck | 14,7256 |
| 稳定性 | 自购买之日起 2 年内保持稳定。 DMSO 或蒸馏水中的溶液可在 -20°C 下储存长达 3 个月。 |
| InChI | 1S/C18H22ClNO.ClH/c1-16(15-21-18-10-6-3-7-11-18)20(13-12-19)14-17-8-4-2-5-9-17;/h2-11,16H,12-15H2,1H3;1H |
| InChIKey | VBCPVIWPDJVHAN-UHFFFAOYSA-N |
| SMILES | Cl[H].CC(COc1ccccc1)N(CCCl)Cc2ccccc2 |
| CAS 数据库 | 63-92-3(CAS DataBase Reference) |
| (IARC)致癌物分类 | 2B (Vol. 24, Sup 7) 1987 |
| EPA化学物质信息 | N-(2-Chloroethyl)-N-(1-methyl-2-phenoxyethyl)benzylamine hydrochloride (63-92-3) |
盐酸酚苄明 用途与合成方法
| Target | Value |
| α-adrenergic receptor |
The IC 50 (100 nM) derived from the blockade of [ 3 H]yohimbine binding by Phenoxybenzamine hydrochloride is significantly less than the IC 50 (550 nM) for the corresponding reversal by Phenoxybenzamine hydrochloride of the effects of norepinephrine on cyclic AMP accumulation. Phenoxybenzamine hydrochloride (50 nM) in conbination with Phenoxybenzamine hydrochloridetolamine (1000 nM) enhances Phenoxybenzamine hydrochlorideylephrine-induced contraction compared with pretreatment with Phenoxybenzamine hydrochloride (50 nM) alone in endothelium-intact aortae. Combined treatment with either dexmedetomidine (300 or 1000 nM) and Phenoxybenzamine hydrochloride (50 nM) or Phenoxybenzamine hydrochloridetolamine (1000 nM) and Phenoxybenzamine hydrochloride (50 nM) enhance Phenoxybenzamine hydrochlorideylephrine-induced contraction compared with Phenoxybenzamine hydrochloride alone (50 nM). In addition, combined treatment with Phenoxybenzamine hydrochloridetolamine and Phenoxybenzamine hydrochloride enhances Phenoxybenzamine hydrochlorideylephrine-induced contraction compared with dexmedetomidine (1000 nM) and Phenoxybenzamine hydrochloride combined treatment. Combined treatment with high concentrations of dexmedetomidine (1000 nM) and Phenoxybenzamine hydrochloride enhances Phenoxybenzamine hydrochlorideylephrine-induced contraction compared with combined treatment with low concentrations of dexmedetomidine (300 nM) and Phenoxybenzamine hydrochloride. Phenoxybenzamine hydrochloride (0.1-100 μM) inhibits glioma proliferation, migration, and invasion and suppresses the tumorigenesis capacity. Phenoxybenzamine hydrochloride also inhibits self-renewal of glioma stem-like cells. Phenoxybenzamine hydrochloride activates LINGO-1 and inhibits the TrkB-Akt pathway. Phenoxybenzamine hydrochloride (0.1 μM-1 mM) preserves primary neurons within the CA1, CA3 and dentate gyrus and produces a robust neuroprotective effect, and prevents neuronal death from OGD in all regions of the hippocampus when delivered at 2, 4, and 8 h post-OGD at 100 μM.
Phenoxybenzamine hydrochloride (20 nM, s.c.) effectively suppresses the tumorigenesis of glioma cells in mice and the cell density in Phenoxybenzamine hydrochloride-U87MG xenografts decreases significantly. Phenoxybenzamine hydrochloride (1 mg/kg, i.v.) treated rats shows significant improvements in NSS and foot fault scoring.
101-45-1
63-92-3
在25-30℃条件下,将N-(苯氧基异丙基)-N-苄基乙醇胺溶解于二氯甲烷(810 mL)中。随后,在0-5℃下缓慢滴加亚硫酰氯(70.0 g, 0.588 mol)。反应混合物于25-30℃持续搅拌2小时。反应完成后,于30-35℃下进行减压浓缩。将浓缩后的残余物于25-30℃溶解于丙酮(570 mL)中,促使固体形成。通过过滤收集固体,并用冷却的丙酮(190 mL)洗涤。最后,将固体于45-50℃下进行真空干燥,得到125.4 g高纯度的苯氧基苯甲胺盐酸盐,呈白色固体(HPLC纯度 > 99%)。
参考文献:
[1] Patent: WO2018/130942, 2018, A1. Location in patent: Page/Page column 10; 12
安全信息
| 危险品标志 | Xn |
|---|---|
| 危险类别码 | 22-40 |
| 安全说明 | 22-36/37/39-45 |
| WGK Germany | 3 |
| RTECS号 | DP3750000 |
| 海关编码 | 2922299000 |
| 存储类别 | 11 - 可燃固体 |
| 危险性类别 | 急性毒性 类别4 经口 致癌性 类别2 |
盐酸酚苄明 化学药品说明书
盐酸酚苄明 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-03-03 | S2499 | 盐酸酚苄明 | 63-92-3 | 50mg | 788.04 |
| 2026-03-03 | S2499 | 盐酸酚苄明 | 63-92-3 | 10mM(1mL in DMSO) | 1070.87 |